ÂÜÀòÂÒÂ×

Tongfei Wu has a wide range of work experience in the pharmaceutical and biotechnology industries. Tongfei most recently held the position of Senior Director-Medchem & Project Leader at Aligos Therapeutics, starting in January 2022. Prior to that, they served as Director at the same company from January 2021 to December 2021, and as Associate Director from October 2019 to December 2020.

Before joining Aligos Therapeutics, Wu worked at Galapagos as a Principal Scientist & Chemistry Team Leader from May 2018 to September 2019. Tongfei also had a long tenure at Janssen, Pharmaceutical Companies of Johnson and Johnson, where they held various roles. Starting as a Scientist in August 2005, they later became a Senior Scientist and Chemistry Team Leader for the discovery of a potent and orally bioavailable PRMT5 inhibitors. During their time at Janssen, Wu received the Outstanding Scientist Award in 2016 and the Johnson & Johnson Standards of Leadership Award in 2017.

Wu's earlier experience includes a role as a Visiting Scientist at the Whitehead Institute for Biomedical Research, MIT, from September 2012 to February 2013.

Overall, Tongfei Wu has accumulated extensive experience in leadership positions, project management, and scientific research in the pharmaceutical and biotechnology sectors.

Tongfei Wu completed a Ph.D. in Medicinal Chemistry from KU Leuven, from 2001 to 2005. Prior to that, from 1998 to 2001, they obtained a Master's and Bachelor's degree in Organic Chemistry from The Graduate School of Chinese Academy of Sciences.